Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Caris Life Sciences (CAI) EBITDA Margin (2024 - 2025)

Caris Life Sciences has reported EBITDA Margin over the past 2 years, most recently at 28.05% for Q4 2025.

  • Quarterly results put EBITDA Margin at 28.05% for Q4 2025, up 5648.0% from a year ago — trailing twelve months through Dec 2025 was 0.21% (changed N/A YoY), and the annual figure for FY2025 was 8.3%, up 6008.0%.
  • EBITDA Margin for Q4 2025 was 28.05% at Caris Life Sciences, up from 11.25% in the prior quarter.
  • Over the last five years, EBITDA Margin for CAI hit a ceiling of 28.05% in Q4 2025 and a floor of 66.77% in Q3 2024.